People: Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

1:30am IST
Change (% chg)

$-1.36 (-2.10%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Aurentz, Vincent 

Mr. Vincent E. Aurentz serves as Executive Vice President and Chief Business Officer of the Company. Mr. Aurentz has served as our Executive Vice President and Chief Business Officer since August 2016. Mr. Aurentz has almost 30 years of experience in the biopharmaceutical industry. Previously, he was the Chief Business Officer of Epirus Biopharmaceuticals, Inc. from November 2015 to July 2016. Prior to that, Mr. Aurentz served as President and was a member of the Board of Directors of HemoShear Therapeutics, LLC from July 2013 to November 2015, where he oversaw the scientific platform, R&D activities, commercial and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children’s National Health System. Prior to joining HemoShear, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono S.A.) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. Mr. Aurentz is a former Executive Vice President at Quintiles and a Co-founder and Managing Director of a venture capital and advisory business. He was a partner with CSC Healthcare, the life sciences strategic management consulting division of Computer Sciences Corporation, after starting his career and working for 8 years at Andersen Consulting (now Accenture). In July 2016, Epirus filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Mr. Aurentz received a B.S. in mathematics from Villanova University.

Basic Compensation

Total Annual Compensation, USD 701,810
Restricted Stock Award, USD 1,095,030
Long-Term Incentive Plans, USD --
All Other, USD 1,652,560
Fiscal Year Total, USD 3,449,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 65,000 1,655,200.00
Name Fiscal Year Total

Tina Nova


Amit Munshi


Laurie Stelzer


Joan Schmidt


Vincent Aurentz


Robert Lisicki

As Of  31 Dec 2019